SLC5A2 and type 2 diabetes mellitus: In conclusion, the non-inferiority in relation to MACE indicated the cardiovascular safety of SGLT2 inhibitors in patients with type 2 diabetes with prior cardiovascular disease or at elevated risk for cardiovascular disease.